Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells

Wanlin Yang,1,* Hongshuang Yu,2,* Jiefang Huang,2 Xiang Miao,2 Qiwei Wang,4 Yanan Wang,1,4 Yiji Cheng,5 Shan He,1 Fang Zhao,1 Lijun Meng,1 Bei Wang,2 Fengtao Qian,2 Xiaohui Ren,2 Min Jin,2,5 Yuting Gu,5,§ Yanyun Zhang,1,2,4,§ and Wei Cai3,§

1Children’s Hospital of Soochow University, Institutes for Translational Medicine, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Soochow University, Suzhou, China; 2Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China; 3Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; and 5Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

SUMMARY
EPZ-5676, inhibitor of Dot1L, is a potential strategy for fulminant hepatitis treatment. Dot1L inhibition dramatically enhanced the immunosuppressive function of myeloid derived suppressor cells. Mechanistically, Dot1L inhibition epigenetically suppressed SOCS1 expression, inducing inducible nitric oxide synthase expression in a STAT1-dependent manner.

BACKGROUND & AIMS: Fulminant hepatitis (FH) is a clinical syndrome characterized by sudden and severe liver dysfunction. Dot1L, a histone methyltransferase, is implicated in various physiologic and pathologic processes, including transcription regulation and leukemia. However, the role of Dot1L in regulating inflammatory responses during FH remains elusive.

METHODS: Propionibacterium acnes (P. acnes)-primed, lipopolysaccharides (LPS)-induced FH was established in C57BL/6 mice and was treated with the Dot1L inhibitor EPZ-5676. Myeloid derived suppressor cells (MDSCs) were depleted by anti-Gr-1 antibody to evaluate their therapeutic roles in Dot1L treatment of FH. Moreover, peripheral blood of patients suffered with FH and healthy controls was collected to determine the expression profile of Dot1L-SOCS1-iNOS axis in their MDSCs.

RESULTS: Here we identified that EPZ-5676, pharmacological inhibitor of Dot1L, attenuated the liver injury of mice subjected to FH. Dot1L inhibition led to decreased T helper 1 cell response and expansion of regulatory T cells (Tregs) during FH. Interestingly, Dot1L inhibition didn’t directly target T cells, but dramatically enhanced the immunosuppressive function of MDSCs. Mechanistically, Dot1L inhibition epigenetically suppressed SOCS1 expression, thus inducing inducible nitric oxide synthase (iNOS) expression in a STAT1-dependent manner. Moreover, in human samples, the levels of Dot1L and SOCS1 expression were upregulated in MDSCs, accompanied by decreased expression of iNOS in patients with FH, compared with healthy controls.

CONCLUSIONS: Altogether, our findings established Dot1L as a critical regulator of MDSC immunosuppressive function for the first time, and highlighted the therapeutic potential of Dot1L inhibitor for FH treatment. (Cell Mol Gastroenterol Hepatol 2021;12:81–98; https://doi.org/10.1016/j.jcmgh.2021.01.013)

Keywords: Fulminant Hepatitis; Histone Methyltransferase Dot1L; Inducible Nitric Oxide Synthase; Myeloid-Derived Suppressor Cells.
Fulminate hepatitis (FH), characterized by severe hepatocellular dysfunction followed by hepatic coagulopathy or encephalopathy, is a potentially fatal clinical syndrome, which develops secondary to infection, side effects of drugs, toxins, alcohol abuse, or metabolic syndrome. The mechanisms leading to such profound hepatic damage are not fully understood, but circumstantial evidence suggests that poorly controlled inflammatory responses play a major role in the pathogenesis of FH. Abundant immune cells infiltrate into the liver and produce a large number of pro-inflammatory cytokines thus inducing apoptosis and necrosis of hepatocytes. Although many pharmacological approaches have been proposed to recover liver function, liver transplantation is still the current gold standard of care. However, use of liver transplantation is limited by transplantation-related problems, such as lack of donors, risk of rejection, and side effects of immunosuppressive drugs.

Liver immune homeostasis is controlled by epigenetic histone modifications including histone methylation and acetylation. Aberrant histone modifications comprise an important mechanism in pathogenesis of liver diseases. Thus, interfering with the function of histone regulators may be a beneficial approach to the development of novel therapeutic strategies. Disruptor of telomeric silencing-1-like (Dot1L), a major histone methyltransferase, catalyzes mono-, di-, and trimethylation on histone 3 lysine 79 (H3K79), which is often associated with gene transcriptional activation. Dot1L has several known functions in immunity. First, Dot1L is required for the maintenance of hematopoietic stem cells and lineage-specific progenitors in homeostatic conditions. Second, as a highly conservative protein in different species, Dot1L is widely expressed in various kinds of immune cells of mice and humans. Third, both innate and adaptive immune responses are modulated by Dot1L via promoting interleukin (IL)-6 and interferon (IFN)-β expression from macrophages, regulating low-avidity T cell responses and controlling the activation threshold in human T cells. However, the roles of Dot1L and H3K79 methylation mediated by Dot1L in the pathogenesis of FH and the underlying immunoregulatory mechanism remain elusive.

Tolerogenic regulators play important roles in maintaining immune tolerance in liver and restraining inflammation-induced liver injury. One of the main regulators is myeloid-derived suppressor cells (MDSCs), a heterogeneous population of myeloid cells derived from bone marrow (BM), which exert immunosuppressive effects on both innate and adaptive immune responses to foster immune tolerance. MDSCs have been implicated to link with T cell dysfunction in chronically hepatitis B virus (HBV) infected patients. In mouse models of liver injury, MDSCs also exhibited immunosuppressive function through impairing proliferation and proinflammatory cytokine secretion of liver-infiltrating T cells, thus protecting against hepatic inflammation and hepatocyte dysfunctions. Recently, several groups reported that histone methylation might regulate the generation of MDSCs from hematopoietic progenitor cells. However, whether Dot1L is effective in regulating the immunosuppressive function of MDSCs and the underlying mechanism is still poorly understood.

In this study, using Propionibacterium acnes–primed, lipopolysaccharide (LPS)-induced FH in mice, we found that interference with Dot1L activity using pharmacological inhibitor attenuated the severity of liver injury and mortality of FH in mice. The protective role of Dot1L inhibition was attributed to increased inducible nitric oxide synthase (iNOS) expression of MDSCs, which inhibited T helper 1 (Th1) cell response and induced regulatory T cell (Treg) expansion. The molecular and genetic evidence further demonstrated that Dot1L served as a positive regulator of suppressor of cytokine signaling 1 (SOCS1), which in turn inhibited the signal transducer and activator of transcription 1 (STAT1) signaling pathway and restrained the expression of iNOS in MDSCs. Therefore, our study suggests Dot1L as a potential therapeutic target for acute liver injury and associated diseases.

## Results

### Inhibition of Dot1L Alleviates Mouse Mortality and Severity of P. acnes–Induced Liver Injury

To determine the role of Dot1L during FH pathogenesis, EPZ-5676, an inhibitor of Dot1L, or vehicle was injected intraperitoneally after *P. acnes* priming. For the vehicle-treated group, all mice died within 20 hours after LPS injection. In contrast, EPZ-5676–treated mice significantly improved the survival rate of FH, and all mice survived more than 48 hours (Figure 1A).

Liver injury of this model occurs in 2 phases: the early priming and the late elicitation phases. During the priming phase, *P. acnes* injection resulted in granuloma formation, whereas massive hepatocellular damage induced by LPS injection occurred during the elicitation phase. We found that the EPZ-5676–treated mice had markedly reduced granulomas in liver and significantly reduced weight of liver and spleen, compared with control mice, whether injected with LPS or not after *P. acnes* priming (Figure 1B and C). Consistently, there were dramatic changes in hepatic inflammation and fibrosis scores (Figure 1D).
reduction of alanine aminotransferase and aspartate aminotransferase, which are hallmarks of hepatitis-induced liver failure, in the serum of EPZ-5676–treated mice (Figure 1D). In addition, histological analysis showed that livers isolated from mice treated with EPZ-5676 displayed smaller nodules and much less infiltration of lymphocytes (Figure 1E). We also found that administration of EPZ-5676 could significantly reduce the Fas ligand expression (Figure 1F) and the level of TUNEL+ (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling positive) cells (Figure 1G), indicating a lower level of hepatocyte apoptosis in liver.
Taken together, these data collectively suggested that EPZ-5676 treatment effectively attenuated the severity of bacteria-induced liver injury and improved the survival rate of FH.

**Dot1L Inhibition Reduces Activation and Proliferation of CD4⁺ T Cells**

It is known that CD4⁺ T cell-mediated inflammation plays an important role in P. acnes–induced liver injury. Mononuclear cells (MNCs) accumulated significantly in the liver and spleen of P. acnes-primed control mice (Figure 2A), and both the percentage and absolute number of CD4⁺ T cells increased dramatically in the liver and spleen (Figure 2B and C). By contrast, infiltration of MNCs and CD4⁺ T cells decreased significantly both in the liver and spleen of EPZ-5676–treated mice (Figure 2A–C). To detect the proliferation of CD4⁺ T cells, we injected BrdU (5-bromo-2-deoxyuridine), a synthetic nucleoside that could be incorporated into newly synthesized DNA to monitor the cell proliferation, into EPZ-5676–treated or P. acnes-primed control mice. The flow cytometric analysis revealed that EPZ-5676 treatment decreased the frequencies of BrdU⁺ CD4⁺ T cells in the liver and spleen after P. acnes priming (Figure 2D), suggesting that Dot1L inhibition may regulate the proliferation of CD4⁺ T cells in vivo. In addition, EPZ-5676–treated mice showed decreased CD44hiCD62Llo CD4⁺ T cells and increased CD62LhiCD44lo CD4⁺ T cells (Figure 2E), suggesting that Dot1L inhibition suppressed CD4⁺ T cell activation in vivo. We also found reduced expression of chemokine receptors, such as CXCR3 and CCR7 on CD4⁺ T cells (Figure 3A and B) and their respective chemokines CXCL9, CXCL10, and CCL21 in the liver of EPZ-5676–treated mice (Figure 3C). These results indicated that Dot1L inhibition also suppressed the chemotaxis of pathogenic CD4⁺ T cells into the liver.
Dot1L Inhibition Suppresses Th1 Cells While Promotes Tregs in the Liver But Not in In Vitro Culture

We previously identified Th1 cells as major pathogenic contributor of P. acnes–induced liver injury. Thus, serum levels of Th1 cytokines IFN-γ and tumor necrosis factor α (TNF-α), Th2 cytokine IL-4, and Th17 cytokine IL-17 were determined. EPZ-5676 treatment reduced levels of TNF-α and IFN-γ significantly (Figure 4A) but had no effect on IL-4 or IL-17 production (Figure 4B). Intracellular staining of IFN-γ and TNF-α further confirmed the reduction of IFN-γ– (Figure 4C) and TNF-α–positive cells (Figure 4D) after EPZ-5676 treatment within CD4+ T cells. By contrast, administration of EPZ-5676 significantly increased CD4+ Foxp3+ Tregs as compared with the vehicle treatment (Figure 4E). These data demonstrated that Dot1L inhibition suppressed Th1 cells but promoted Tregs in the liver.

To further explore whether EPZ-5676 treatment impaired CD4+ T cell response during FH pathogenesis through a direct or indirect way. We tested the effect of EPZ-5676 on CD4+ T cells in vitro culture. However, Dot1L inhibition was dispensable for the in vitro CD4+ T cell activation, proliferation and production of Th1 cytokines, as characterized by comparable CD25 and CD69 expression (Figure 5A), proliferation rate (Figure 5B), IFN-γ, and TNF-α production (Figure 5C) of EPZ-5676 or vehicle-treated T cells upon the stimulation of anti-CD3 plus anti-CD28 antibodies. Moreover, percentage of CD4+ Foxp3+ Tregs were also comparable between EPZ-5676 and vehicle-treated T cells (Figure 5D). Collectively, these results suggested that Dot1L inhibition restricted the CD4+ T cell response through an indirect mechanism during FH pathogenesis.

Inhibition of Dot1L Increases Immune Suppressive Ability of MDSCs

To figure out which type of cells in vivo were directly targeted by EPZ-5676 to protect against FH-induced liver failure, we examined the infiltration status of non–T cells in the liver and spleen. The results revealed EPZ-5676 treatment and P. acnes–primed control mice had similar frequencies of CD11c+ dendritic cells (DCs) (Figure 6A), F4/80+ Kupffer cells (Figure 6B), and neutrophils (Figure 6C) in the liver. Next, we investigated whether EPZ-5676 treatment could influence the activation and function of DCs and Kupffer cells. EPZ-5676 treatment did not affect the expression of major histocompatibility complex class II and costimulatory molecules CD86 in both CD11c+ DCs (Figure 6D) and F4/80+ Kupffer cells (Figure 6E) in the liver. These data demonstrated that EPZ-5676 did not affect infiltration and activation of DCs, Kupffer cells, and neutrophils during FH pathogenesis.

However, EPZ-5676 treatment notably increased the frequencies of CD11b+ Gr-1+ MDSCs in the spleen (Figure 7A) and liver (Figure 7B) at day 7, whether injected with LPS or not after P. acnes priming. Notably, 5 μM EPZ-
5676 significantly enhanced the induction of MDSCs from BM cells (Figure 7C), without apparently affecting their apoptosis (Figure 7D). In addition, in vitro proliferation assay revealed that EPZ-5676–pretreated MDSCs exhibited enhanced ability to suppress T cell proliferation compared with control MDSCs, after co-cultured with CD4⁺ T cells that stimulated with anti-CD3 plus anti-CD28 antibodies (Figure 7E).

We next examined whether the depletion of liver recruitment of MDSCs impaired the alleviation of FH in EPZ-5676–treated mice. To this end, we specifically deleted the MDSCs by injection of anti-Gr-1 neutralizing antibody (Figure 7F) and challenged mice with P. acnes/ LPS to induce FH. As expected, in vivo MDSC depletion largely abolished the difference of the survival rate between EPZ-5676–treated and P. acnes–primed control mice (Figure 7G). These results collectively established Dot1L inhibition as a critical mediator of MDSC suppressive function to protect inflammation-induced liver injury during FH pathogenesis.

**Inhibition of Dot1L Enhances Suppressive Function of MDSCs by Increasing iNOS Expression Through STAT1 Signaling**

We next investigated the mechanisms by which Dot1L regulated the immunosuppressive activity of MDSCs. Several immunosuppressive factors, such as IDO (indoleamine 2,3-dioxygenase), iNOS, cyclooxygenase-2 (COX2), transforming growth factor-β (TGF-β), Arg1 (arginase 1), and IL-10 are known to suppress T cell response by MDSCs. Among these suppressive factors, the expression of iNOS was the most strongly induced in the MDSCs treated by EPZ-5676 (Figure 8A). By contrast, the expression levels of IDO, COX2, TGF-β, Arg1, and IL-10 were not significantly changed by the Dot1L inhibition (Figure 8A). Western blot assay confirmed that the expression level of iNOS was increased in the EPZ-5676–treated MDSCs (Figure 8B). Accordingly, the concentration of NO in EPZ-5676–treated MDSC supernatant fraction significantly increased (Figure 8C). Furthermore, a functional study showed that L-NMMA, a specific inhibitor
of iNOS activity, reversed the enhanced suppressive effects of EPZ-5676–treated MDSCs on T cell proliferation (Figure 8D). These data indicated that inhibition of Dot1L enhanced the immunosuppressive capacity of MDSCs mainly through upregulating iNOS expression.

We further investigated the effect of Dot1L inhibition on the signal pathways involved in iNOS expression through detection of the phosphorylation status of MAPK (mitogen-activated protein kinase), nuclear factor κB, and the STAT signaling pathway. No substantial difference was noted in the phosphorylation of ERK, JNK, p38, p65, and IκBα between EPZ-5676–treated MDSCs and control cells (Figure 8E). Hence, Dot1L exerted no effect on the activation of the MAPK and nuclear factor-κB pathways in the MDSCs. These results promote us to investigate the role of STAT signaling pathway in these cells. No differences in phosphorylation of STAT1 at Ser727 (p-STAT1-Ser727) and other members in STAT signaling pathway were observed between EPZ-5676–treated MDSCs and control cells. However, Dot1L inhibition considerably increased the phosphorylation of STAT1 levels at Tyr701 (p-STAT1-Tyr701) in the EPZ-5676–treated MDSCs (Figure 8F). Functionally, treatment with the STAT1 inhibitor nifuroxazide reversed the increased iNOS expression (Figure 8F and G) and NO production in EPZ-5676–treated MDSCs (Figure 8H). As a result, the enhanced suppressive effects on T cell proliferation by EPZ-5676–treated MDSCs were abolished upon the treatment of nifuroxazide (Figure 8I). Collectively, these data suggested that Dot1L inhibition induced the iNOS expression in MDSCs by activating STAT1 signaling pathway.

**Dot1L Epigenetically Controls SOCS1 Expression in MDSCs**

To further dissect the mechanistic role of Dot1L in regulating activation of STAT1 signaling, expression of SOCSs, negative regulation factors of STAT1 signaling
We detected RNA expression of SOCSs in the EPZ-5676–treated and control MDSCs and found that SOCS1 was the most downregulated one in MDSCs treated with EPZ-5676 (Figure 9A and B). We next investigated the mechanisms by which Dot1L regulates SOCS1. In most cases, Dot1L regulates gene expression by adding positive marker H3K79me2 at gene promoters, and thus we hypothesize that Dot1L may directly regulate SOCS1 through epigenetic modification. Chromatin immunoprecipitation (ChIP) assay indicated strong enrichment of H3K79me2 in the promoter regions (–2000 bp to transcription start site) of SOCS1 in control MDSCs (Figure 9C), whereas Dot1L inhibition significantly reduced the H3K79me2 levels at the promoters of SOCS1 (Figure 9C). In the control samples, Dot1L bound to the same promoter regions of SOCS1, and Dot1L inhibition significantly reduced the binding (Figure 9D).

Collectively, these results established SOCS1 as a direct target that was fine-tuned by Dot1L-mediated H3K79me2 in MDSCs.

### Dot1L Expression Is Upregulated in Patients With Fulminant Hepatitis

To evaluate whether the Dot1L-SOCS1-iNOS axis in MDSCs contributes to FH progression, we analyzed Dot1L, SOCS1, and iNOS expression in MDSCs of peripheral blood between patients with FH and healthy control subjects. Owing to lack of appropriate markers for the whole population of MDSCs in human, we detected the expression of Dot1L, SOCS1 and iNOS in granulocytic MDSCs and monocytic MDSCs separately. Consistent with the results in the mouse model of FH, Dot1L (Figure 10A) and SOCS1 (Figure 10B) were upregulated in both granulocytic MDSCs and monocytic MDSCs.
MDSCs, accompanied by decreased expression of iNOS (Figure 10C) in peripheral blood of patients with FH compared with healthy control subjects. Altogether, these data showed that the Dot1L-SOCS1-iNOS axis might contribute to the progression of FH.

**Discussion**

Our findings demonstrate that inhibition of Dot1L effectively attenuates the severity of inflammation-induced liver injury and increases survival rate of mice subjected to *P. acnes* plus LPS-induced FH. In terms of mechanism, Dot1L inhibition enhances immunosuppressive function of MDSCs through increasing the production of iNOS in a STAT1-dependent manner. Moreover, Dot1L inhibition downregulates H3K79me2 level at the promoters of SOCS1, which is responsible for the activation of STAT1 signaling pathway in MDSCs. These MDSCs inhibit Th1 cells and induce Tregs, resulting in amelioration of FH.
Figure 8. Inhibition of Dot1L enhances suppressive function of MDSCs by increasing iNOS expression through STAT1 signaling. BM cells of C57BL/6 mice were cultured in the presence of GM-CSF and IL-6 to induce MDSC differentiation in vitro, and were treated by vehicle (control) or EPZ-5676 (5 μM) for 4 days, then the mRNA, protein, and supernatant were collected. (A) mRNA expression levels of indicated genes, were measured by quantitative real-time PCR. (B) Protein expression level of iNOS was measured by immunoblotting. (C) The concentration of NO in cultural supernatant was detected by Griess reagent. (D) Control or EPZ-5676–treated MDSCs were also treated with L-NMMA (10 μM) and purified MDSCs were co-cultured with CFSE-labeled CD4\(^+\) T cells activated by anti-CD3/CD28 antibodies for 3 days at indicated ratios. CD4\(^+\) T cells were stained for proliferation analysis by flow cytometry at the end of co-culture. Data are presented representative histograms at ratio of 1:8 and bar graph. (E) The expression levels of indicated protein were measure by immunoblotting. (F–H) Control or EPZ-5676–treated MDSCs were also treated with nifuroxazide (10 μM). Expression of iNOS was measured by (F) quantitative-real time PCR and (G) immunoblotting. (H) The concentration of NO in cultural supernatant was detected by Griess reagent. (I) Purified MDSCs were co-cultured with CFSE-labeled CD4\(^+\) T cells activated by anti-CD3/CD28 antibodies for 3 days at indicated ratios. CD4\(^+\) T cells were stained for proliferation analysis by flow cytometry at the end of co-culture. Data are presented representative histograms at ratio of 1:8 and bar graph. Results are representative of 3–5 independent experiments and presented as mean ± SD. Significant differences were analyzed by (A, D–I) 2-way analysis of variance, (B, C) Mann–Whitney U test, and expressed as *P < .05, **P < .01, ***P < .001, n.s., not significant.
Recent conceptual advances support an important role of MDSCs as a key inhibition factor of FH.\textsuperscript{17,18} However, important knowledge gaps remain as to how epigenetic modifications regulate suppressive function of MDSCs to influence the inflammatory-induced liver injury process. In this context, the current study provides several advances: (1) Dot1L inhibition enhances immunosuppressive function of MDSCs through increasing the production of iNOS; (2) Dot1L induces transcription of SOCS1 by mediating H3K79me2 at its promoters, leading to repression of STAT1-dependent iNOS expression; (3) pharmacologic inhibition of Dot1L protects animals against inflammatory liver injury, while MDSC depletion impairs therapeutic effect of Dot1L inhibition on FH. Although our studies corroborate the paradigm that epigenetic regulators restrain the injury by MDSCs, the primary significance of these studies lies in the paradigm that epigenetic regulators restrain the suppressive function of MDSCs in inflammatory disease. These changes promote pathogenic CD4\textsuperscript{+} T cells activation and progression of liver injury. In turn, interventions targeting these newly discovered pathways may have the capability to prevent, delay, or reverse the inflammatory response that drive FH.

FH is a life-threatening disease and liver transplantation is the only definitive treatment for the acute liver injury. However, the obvious limitations of transplantation, such as shortage of donor, immune rejection, and side effect of immunosuppressive drugs, etc., suggested an urgency to develop novel therapeutic strategies.\textsuperscript{1,5,28} Recently, histone methylation has been considered to be involved in the regulation of liver injury.\textsuperscript{29,30} For example, EZH2, which catalyzes H3K27me3, contributed to the pathogenesis of liver failure through triggering TNF and other indispensable proinflammatory cytokines.\textsuperscript{31} We found that inhibition of Dot1L, a H3K79 methyltransferase, ameliorated liver injury, and improved survival rate of FH in mice through inhibiting activation, proliferation, and cytokine production of CD4\textsuperscript{+} T cells in vivo. However, we demonstrated that Dot1L inhibitor did not affect T cell responses when administrated in vitro culture. Earlier study suggested that Dot1L inhibition prevented allogeneic T cell responses and attenuated the development of graft-vs-host disease, while retaining potent antitumor activity in adoptive immunotherapy models.\textsuperscript{13} However, Dot1L inhibition selectively ameliorated low-avidity T cell responses but not high-avidity T cell responses mediated by the T cell receptor.\textsuperscript{11} Thus, Dot1L inhibition restricted the CD4\textsuperscript{+} T cell response through an indirect mechanism during FH pathogenesis.

MDSCs are critical to maintain the immunosuppressive niche in inflamed liver during the pathogenesis of various kinds of human hepatitis and related mouse models, and increased infiltration of MDSCs effectively attenuates the liver inflammation and protects inflammation-induced acute liver failure.\textsuperscript{17,18,31,32} Although our study showed that mice with \textit{P. acnes}-induced liver injury contained more CD11b\textsuperscript{+} Gr-1\textsuperscript{+} MDSCs than naive mice, it is not surprising. Because, it has been reported that inflammation is required for induction of MDSCs, and Th1 cells induce the accumulation of MDSCs in the liver by production of IFN-\gamma.\textsuperscript{33,34} Most of these studies focused on the mechanism of MDSC generation from HSPCs or recruitment of MDSCs into the liver during liver injury.\textsuperscript{17,18} Our study also found increased percentage of MDSCs in the liver, spleen, and peripheral blood. Thus, Dot1L inhibition attenuated both hepatic and peripheral inflammation in the \textit{P. acnes}-induced acute liver injury. Considering the known function of Dot1L on hematopoiesis, by maintenance of hematopoietic stem cells and lineage-specific progenitors in homeostatic conditions,\textsuperscript{10} we also tested the development of MDSCs upon Dot1L inhibition. We proved that EPZ-5676 promoted BM cells to differentiate into MDSCs in vitro without affecting their apoptosis. However, the molecular mechanism through which driving the immunosuppressive function of MDSCs in the inflamed liver remains elusive.

MDSCs have been shown to exert their immunoregulatory effects through expression of immune suppressive factors such as arginase (encoded by Arg1), iNOS, and COX2, and an increase in the secretion of TGF-\beta and IL-10.\textsuperscript{35} Among those immune suppressive factors, only iNOS expression was significantly increased with decreased level of H3K79me2 upon Dot1L inhibitor treatment, which resulted in increased production of NO in the surrounding of MDSCs, leading to T cell cycle arrest and proliferation inhibition.\textsuperscript{36} In addition, NO depletion via L-NMMA reversed the enhanced immunosuppression in Dot1L-inhibited MDSCs. These results suggested that Dot1L negatively regulated the expression of iNOS by H3K79me2. Moreover, we showed that this process was mediated by activation of STAT1 signaling pathway. STAT1 is the major transcription factor activated by IFN-\gamma signaling in the tumor microenvironment, the upregulation of iNOS expression in MDSCs involved a STAT1-dependent mechanism. Indeed, MDSCs from STAT1\textsuperscript{−/−} mice failed to upregulate iNOS expression and therefore did not inhibit T cell responses.\textsuperscript{36} Consistently, our study demonstrated that the activation level of STAT1 was significantly increased upon Dot1L inhibition in MDSCs, while after inhibition of STAT1 signaling using specific inhibitor-Nifuroxazide, the increased expression of iNOS and NO production resulted from intervening Dot1L-mediated H3K79me2 was abolished. These results suggested that Dot1L inhibition mediated immunosuppressive function of MDSCs through induction of iNOS expression in a STAT1 signaling-dependent manner.

Dot1L functions cover various physiologic and pathologic processes, including transcription regulation, cell cycle regulation, DNA repair, embryonic hematopoiesis, cardiac function, and leukemia.\textsuperscript{9,10} All these are dependent on its H3K79 methyltransferase activity. Genome-wide analysis indicates a tight connection between H3K79 methylation and gene transcription activity. In \textit{Saccharomyces cerevisiae} and flies, Dot1L and H3K79me2 are both found at the promoters of transcriptionally active genes.\textsuperscript{37,38} H3K79me2 modifications also exist in many promoters of transcriptionally active genes in mammalian cells.\textsuperscript{39} Dot1L-mediated H3K79me2/3 modifications appear around transcription start site regions of the \textit{Il6} and \textit{Ifnb1} promoters, resulting increased IL-6 and IFN-\beta production.\textsuperscript{12} Similarly, in our study, we have shown that Dot1L-mediated H3K79me2
directly targets SOCS1 for its transcriptional activation. It is known that SOCS1 is an inhibitor of STAT1 signaling pathway, which explains increased iNOS expression in MDSCs and inhibited T cell responses in FH upon Dot1L inhibition. As no report has shown that Dot1L contains a specific DNA-binding domain, Dot1L may specifically target specific promoters via other binding proteins. AF9 acts as a bridge protein to recruit Dot1L to transcriptionally active genes decorated with H3K9ac and helps maintain the open chromatin state. AF10 recognizes unmodified H3K27, but not methylated H3K27, and recruits Dot1L to specific genomic regions. Thus, other proteins or noncoding RNAs may be involved in the selective recruitment of Dot1L to the SOCS1 promoter in MDSCs, which needs to be further explored.

EPZ-5676 (pinometostat) used in this study, a first-in-class small-molecule inhibitor of Dot1L, completed phase I clinical trials for the treatment of patients with relapsed or refractory acute leukemia bearing a rearrangement of the MLL gene (https://clinicaltrials.gov/ct2/show/NCT01684150 and https://clinicaltrials.gov/ct2/show/NCT02141828). These studies suggested that administration of EPZ-5676 was generally safe, and have modest therapeutic activity in treatment of adult acute leukemia. In conclusion, we showed that Dot1L inhibitor EPZ-5676 has profound inhibitory effects on inflammatory responses and that it ultimately improves survival in mice undergoing P. acnes plus LPS-induced FH. Furthermore, we demonstrated that Dot1L-mediated H3K79me2 directly targeted and promoted the expression of SOCS1. Dot1L inhibition-induced downregulation of SOCS1 mediates activation of STAT1 signaling pathway, leading to increased production of iNOS in MDSCs, which inhibited Th1 cell response and induced Tregs expansion. These results indicate that targeting Dot1L using EPZ-5676 may represent a novel and clinically relevant approach to treat this devastating liver disease.

Materials and Methods
Reagents and Mice
EPZ-5676 (Cat. No. S7062), L-NMMA (Cat. No. S2877), and nifuroxazide (Cat. No. S4182) were purchased from Selleckchem (Houston, TX). For in vivo experiments, EPZ-5676 was dissolved in 2% DMSO + 30% PEG 300 + 5% Tween 80 + ddH2O as recommended by Selleckchem. Antibodies against iNOS (Cat. No. 13120), H3K79me2 (Cat. No. 5427), H3 (Cat. No. 4499), GAPDH (Cat. No. 2118), p-p38 (Cat. No. 4511), p38 (Cat. No. 8690), p-ERK (Cat. No. 4370), ERK (Cat. No. 4695), p-JNK (Cat. No. 4668), JNK (Cat. No. 9252), p-p65 (Cat. No. 3033), p65 (Cat. No. 8242), p-IκBα (Cat. No. 2859), IκBα (Cat. No. 4812), p-STAT1 (Tyr701) (Cat. No. 9167), p-STAT1 (Ser727) (Cat. No. 8826), STAT1 (Cat. No. 9167), p-STAT3 (Tyr705) (Cat. No. 9145), STAT3 (Cat. No. 9132), p-STAT5 (Tyr694) (Cat. No. 9359), STAT5
(Cat. No. 25656), p-STAT6 (Tyr641) (Cat. No. 9361), and STAT6 (Cat. No. 9362) were all purchased from Cell Signaling Technology (Danvers, MA). \textit{P. acnes} (Cat. No. 11827) was purchased from ATCC (Manassas, VA), and LPS (Cat. No. L2630) was purchased from Sigma-Aldrich (St Louis, MO). C57BL/6 mice were purchased from the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences and maintained under specific pathogen-free conditions in the vivarium of Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences and complied with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.

**Processing of Human Blood Samples**

Peripheral blood samples of HBV-related acute-on-chronic liver failure patients \( (n = 6) \) and healthy control subjects \( (n = 6) \) were collected from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Characterization was based on Asian Pacific Association for the Study of the Liver criteria. Among these HBV-related acute-on-chronic liver failure patients, 2 of them suffered HBV for more than 30 years, 1 for 23 years, 2 for 10 years, and 1 for 5 years. And 4 out of 6 patients were cirrhotic.

**Figure 10. Dot1L expression is upregulated in patients with fulminant hepatitis.** Peripheral blood of patients with FH and healthy control subjects was collected and treated with red blood cell lysis buffer. Expression of (A) Dot1L, (B) SOCS1, and (C) iNOS in monocytic MDSCs \( (\text{gated on Lin}^{+}\text{HLA-DR}^{+}\text{CD14}^{+}\text{cells}) \) and granulocytic MDSCs \( (\text{gated on } \text{CD11b}^{+}\text{CD15}^{+}\text{CD14}^{-}\text{C-D33}^{+/lo}\text{CD66b}^{+}\text{cells}) \) were measured by flow cytometry. Lin contains CD3, CD19, CD20, and CD56. Results are representative of 3–5 independent experiments and presented as mean \( \pm \) SD. (A–C) Significant differences were analyzed by Mann–Whitney \( U \) test and expressed as **\textit{P} < .01.**
| Name          | Sequence                                                                 |
|--------------|--------------------------------------------------------------------------|
| β-actin      | 5'–TGTCCACCTTCTCACGATCATGT-3'                                           |
| reverse      | 5'–AGCTCGAATAGCATCGCCCTAGA-3'                                           |
| FasL forward | 5'–GGTTCCTGCTTTGCTTCTTGTG-3'                                           |
| reverse      | 5'–TCTTCTTATGAGGGTGTGATGT-3'                                           |
| Arg1         | 5'–ATTATCGAGGCGCCTTTCCTC-3'                                            |
| reverse      | 5'–ACAGGCGCTGAGTGTGATGT-3'                                              |
| iNos forward | 5'–ACACCGAGGGATCGAGTGT-3'                                               |
| reverse      | 5'–CGACAGCTAGTTGTTGGGAT-3'                                              |
| Tgfb         | 5'–ATTACGAGGCGCCTTTCCT-3'                                               |
| reverse      | 5'–GCCTTAGTTGGACAGGATCTG-3'                                             |
| Il10         | 5'–GGTGCCTTCTCAGCTCTTC-3'                                               |
| reverse      | 5'–TGGAGGAACTGTCCTATCTG-3'                                              |
| Ido forward  | 5'–GGTACCTCACATGAAATCTG-3'                                              |
| reverse      | 5'–TGGACCCTTGTAACCTG-3'                                                 |
| Socs1        | 5'–CTGCCGCTCTTATGGGGGAC-3'                                              |
| reverse      | 5'–AAAAGCAGTCGAGGATCTCG-3'                                              |
| Socs2        | 5'–CTGCACGAGTGTAATGGAAGG-3'                                             |
| reverse      | 5'–ACGGCAAGCGGACTGAGTCAAATCTG-3'                                        |
| Socs3        | 5'–ATTGCCCTCTACACATGTTG-3'                                              |
| reverse      | 5'–TCCAGTGAATTGTCGATG-3'                                                |
| Socs4        | 5'–CGGATGCGAAGTGTGACAG-3'                                               |
| reverse      | 5'–ACCTCAATGGAGCAACAGCTAAAG-3'                                          |
| Socs5        | 5'–GGTGCCTTCTCAGCTCTTC-3'                                               |
| reverse      | 5'–GCGACAGCGGACTGAGTCAAATCTG-3'                                         |
| Socs6        | 5'–ATTGCCCTCTACACATGTTG-3'                                              |
| reverse      | 5'–TCCAGTGAATTGTCGATG-3'                                                |
| Socs7        | 5'–CTGCCGCTCTTATGGGGGAC-3'                                              |
| reverse      | 5'–AAAAGCAGTCGAGGATCTCG-3'                                              |
| Cish forward | 5'–GGTGCCTTCTCAGCTCTTC-3'                                               |
| reverse      | 5'–GAAATGCGGAGTGGATGGTAAAG-3'                                           |
| Socs1-301    | 5'–CGCAATGATGCGGCTAGCCAG-3'                                             |
| reverse      | 5'–GCACTCTTACTACGTGAGGCA-3'                                             |
| Socs1-744    | 5'–TGCTTGCTGATCTTGAGACC-3'                                             |
| reverse      | 5'–GCACCTTTTACTACGTGAGGCA-3'                                            |
| Socs1-1094   | 5'–GCAAGATGATGCGGCTAGCCAG-3'                                           |
| reverse      | 5'–CCCCAAGCTGTTCCAGC-3'                                                 |
| Socs1-1659   | 5'–ACCAGTCTTGGTACAGCCACAC-3'                                           |
| reverse      | 5'–ACACCGAGGGATCGAGTGT-3'                                               |
| Ccl21 forward| 5'–ATGACCTTTTTCGCCCTAATCGC-3'                                          |
| reverse      | 5'–CCTTTCTCCAGACTTACGTTAGGTTCCCC-3'                                    |
| Cxcl9 forward| 5'–TAAATCTTCTTCTCCTCTCTCTCAGCTAC-3'                                    |
| reverse      | 5'–ACAATCTTCTTCTCCTCTCTCTCAGCTAC-3'                                    |
| Cxcl10 forward| 5'–TGCTGAGGGATAGTTCC-3'                                                |
| reverse      | 5'–GGTCAGGACGAGGATGATTCCAC-3'                                          |

PCR, polymerase chain reaction.
Peripheral blood mononuclear cells obtained from patients using red blood cell lysis buffer.

**Induction of Liver Injury**

Female C57BL/6 mice (8–10 weeks old) were primed intravenously with 1 mg of heat-killed *P. acnes* suspended in 200 µL of phosphate-buffered saline (PBS). For survival analysis, mice were injected intravenously with 1 µg of LPS on day 7 after *P. acnes* priming. For the indicated experiments, EPZ-5676 was administrated at a dose of 35 mg/kg intravenously with 1 mg of heat-killed *P. acnes* priming, 1-mg BrdU (Cat. No. 559619, BD Pharmingen) in 100-µL PBS was intraperitoneally injected into EPZ-5676 or Vehicle-treated mice. The mice were euthanized 12 h after the BrdU administration, and the immune cell suspensions from livers or spleens were prepared for flow cytometric analysis.

**Induction of MDSCs In Vitro**

Murine MDSCs were generated in vitro from the BM of C57BL/6 mice. BM was flushed, and red blood cells were lysed with red blood cell lysis buffer. To obtain MDSCs, the remaining cells were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) (40 ng/mL, Cat. No. AF-315-03-20; PeproTech, Rocky Hill, NJ) and IL-6 (40 ng/mL, Cat. No. AF-216-16-10, PeproTech). Four days later, MDSCs were purified by immunomagnetic separation using biotinylated anti-Gr-1 antibodies (Cat. No. 130-120-829; Miltenyi Biotec, Bergisch Gladbach, Germany) and streptavidin-conjugated MicroBeads (Cat. No. 130-048-101; Miltenyi Biotec) according to manufacturer’s protocol. Cell purity was confirmed by flow cytometric analysis (purity >95%). For differentiation assays, BM cells were cultured in the presence of GM-CSF (10 ng/mL) and IL-6 (10 ng/mL).

**Quantitative Real-Time Polymerase Chain Reaction**

Total RNA was extracted from tissues or cells at indicated time points, and was subsequently extracted with TRizol (Cat. No. 15596018; Invitrogen, Carlsbad, CA) and reverse-transcribed in to complementary DNA using the reverse transcription kit (Cat. No. 2690C; Takara Bio, Kyoto, Japan). The levels of messenger RNA were measured by real-time polymerase chain reaction (PCR) with SYBR Green dye. The expression of individual genes was normalized to the expression of *β*-actin. The gene-specific PCR primers (all for mouse genes) are shown in Table 1.

**TUNEL Assay**

Collected liver tissues were routinely processed into optimal cutting temperature and then were stored at −80°C. For TUNEL assay, apoptotic cells were detected using a TUNEL Apoptosis Detection Kit (Alexa Fluor 488, Cat. No. 40307ES60; YEASEN Biotechnology, Shanghai, China) according to the manufacturer’s instructions.

**Flow Cytometry**

The collected immune cell suspensions from liver or spleen were stained with the indicated antibodies and were subjected to flow cytometry analyses using Cytomar FX LX (Beckman Coulter, Brea, CA). For the intracellular staining of TNF-α, IFN-γ, and Foxp3, the cells were fixed and permeabilized by fixation and permeabilization buffer (Cat. No. 00-5523; eBioscience, San Diego, CA) before staining. Specific monoclonal antibodies were obtained from BD Biosciences (Franklin Lakes, NJ), BioLegend (San Diego, CA), or Thermo Fisher Scientific (Waltham, MA): CD4 (GK1.5), BrdU (3D4), CD44 (IM7), CD62L (MEL-14), TNF-α (MP6-XT22), IFN-γ (XMG1.2), and Foxp3 (MF-14), CD25 (PC61), CD69 (H1.2F3), Gr-1 (RB6-8C5), CD11b (M1/70), CCR7 (4B12), CXCR3 (CXCR3-173), CD11c (N418), F4/80 (BM8), major histocompatibility complex class II (M5/114.15.2), CD86 (GL-1), CD14 (M5E2), CD15 (W6D3), CD11b (ICRF44), CD33 (P67.6), CD66b (G10F5), and HLA-DR (L243). And we used combination of CD3 (HT3a), CD19 (4G7), CD20 (2H7), and CD56 (5.1H11) as Lin cocktail.

**In Vivo BrdU Incorporation**

Seven days after *P. acnes* priming, 1-mg BrdU (Cat. No. 559619, BD Pharmingen) in 100-µL PBS was intraperitoneally injected into EPZ-5676 or Vehicle-treated mice. The mice were euthanized 12 h after the BrdU administration, and the immune cell suspensions from livers or spleens were prepared for flow cytometric analysis.
(Cat. No. 9173, TaKaRa) and heated at 95°C for 5 minutes and fractionated in a 10% sodium dodecyl sulfate–polyacrylamide gel. After electrophoresis, separated proteins were transferred onto PVDF membrane (Cat. No. IPVH00010; Millipore, Burlington, MA) and incubated for 1 hour in 5% bovine serum albumin in PBS at room temperature. The blotting membranes were incubated with primary antibodies overnight at 4°C, extensively washed in PBS containing 0.1% Tween 20 and then incubated with horseradish peroxidase–conjugated secondary antibody (Cat. No. 7074S; Cell Signaling Technology) for 1 hour at room temperature, and washed again. The blotting membranes were detected with chemiluminescent reagents (Cat. No. WBAVDCH01; Millipore).

**Griess Assay**

Fifty-microliter culture supernatant fraction of different treated MDSCs and standards were added to a flat bottomed 96-well-plate, and then 50 μL of Griess reagent A and 50 μL of Griess reagent B (Cat. No. G4410; Sigma-Aldrich) were added sequentially. Read the absorbance at 540 nm after incubation for 15 minutes in the dark at room temperature, and calculated NO concentrations.

**ChIP Assay**

Chromatin of MDSCs (1 × 10^7) was prepared using EZ-ChIP Chromatin Immunoprecipitation Kit (Cat. No. 17-371; Millipore) according to the instructions provided by the manufacturer. Chromatin was immunoprecipitated using anti-Dot1L, anti-H3K79me2 or respective IgGs. ChIP-enriched and input DNA were extracted by PCR Cleanup Kit (Cat. No. AP-PCR-500G; Axygen, Union City, CA) and analyzed by quantitative PCR, with the inputs as the internal control. Primers for ChIP assay were provided in Table 1. Regions of SOCS1 promoter used for ChIP assay were ranged from -2000 bp to transcription start site. This region was averagely divided into 4 parts to cover the promoter area by 1 set of primers per 500 bp.

**Quantification and Statistical Analysis**

All data was showed as mean ± SD and performed at least 3 independent experiments. Significant differences were evaluated using Mann–Whitney U test, except that multiple treatment groups were compared within individual experiments by analysis of variance test. Log-rank test was used for survival analysis. Significance was expressed as *P < .05, **P < .01, and ***P < .001.

**References**

1. Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013;369:2525–2534.
2. Stravitz RT, Lee WM. Acute liver failure. Lancet 2019; 394:869–881.
3. Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatoal 2008; 49:845–861.
4. Possamai LA, Thursz MR, Wendon JA, Antoniades CG. Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure. J Hepatoal 2013;61:439–445.
5. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol 2009; 6:542–553.
6. Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128–145.
7. Mann DA. Epigenetics in liver disease. Hepatology 2014; 60:1418–1425.
8. Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut 2016;65:1895–1905.
9. McLean CM, Karemker ID, van Leeuwen F. The emerging roles of DOT1L in leukemia and normal development. Leukemia 2014;28:2131–2138.
10. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011; 117:4759–4768.
11. Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 25:1345–1358.
12. Chen X, Liu X, Zhang Y, Huai W, Zhou Q, Xu S, Chen X, Li N, Cao X. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages. Cell Mol Immunol 2020;17:76–84.
13. Kagoya Y, Nakatsugawa M, Saso K, Guo T, Anzcuzowski M, Wang C-H, Butler MO, Arrowsmith CH, Hirano N. DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models. Nat Commun 2018;9, 1915–1915.
14. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018; 19:108–119.
15. Pal S, Nandi M, Dey D, Chakraborty BC, Shil A, Ghosh S, Banerjee S, Santra A, Ahammer SKM, Chowdhury A, Datta S. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther 2019; 49:1346–1359.
16. Diao W, Jin F, Wang B, Zhang C-Y, Chen J, Zen K, Li L. The protective role of myeloid-derived suppressor cells in concanavalin A-induced hepatic injury. Protein Cell 2014;5:714–724.
17. Sarra M, Cupi ML, Bernardini R, Ronchetti G, Monte Leone I, Ranalli M, Franzé E, Rizzo A, Colantoni A, Caprioli F, Maggioni M, Gambacurta A, Mattei M, Macdonald TT, Palleone F, Monte Leone G. IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology 2013;58:1436–1450.
18. Xu J, Pei S, Wang Y, Liu J, Qian Y, Huang M, Zhang Y, Xiao Y. Tpl2 Protects against fulminant hepatitis through mobilization of myeloid-derived suppressor cells. Front Immunol 2019;10, 1980–1980.
19. Zhou J, Huang S, Wang Z, Huang J, Xu L, Tang X, Wan YY, Li Q-J, Symonds ALJ, Long H, Zhu B. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Nat Commun 2019; 10, 2427–2427.

20. Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, Wan YY, Long H, Zhu B. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res 2019; 79:2009–2019.

21. Tsuji H, Mukaida N, Harada A, Kaneko S, Matsushita E, Nakanuma Y, Tsutsui H, Okamura H, Nakanishi K, Tagawa Y, Iwakura Y, Kobayashi K, Matsushima K. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN gamma-deficient mice by a concomitant reduction of TNF-alpha, IL-12, and IL-18 production. J Immunol 1999; 162:1049–1055.

22. Tanaka Y, Takahashi A, Kobayashi K, Arai I, Higuchi S, Otomo S, Watanabe K, Habu S, Nishimura T. Establishment of a T cell-dependent nude mouse liver injury model induced by Propionibacterium acnes and LPS. J Immunol Methods 1995;182:21–28.

23. Okazaki T, Ozaki S, Nagaoka T, Kozuki M, Sumita S, Tanaka M, Osakada F, Kishimura M, Kakutani T, Nakao K. Antigen-specific T(h)1 cells as direct effectors of Propionibacterium acnes-primed lipopolysaccharide-induced hepatic injury. Int Immunol 2001; 13:607–613.

24. Yoneyama H, Harada A, Imai T, Baba M, Yoshie O, Zhang Y, Higashi H, Murai M, Asakura H, Matsushima K. Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J Clin Invest 1998;102:1933–1941.

25. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162–174.

26. Durham GA, Williams JLL, Nasim MT, Palmer TM. Targeting SOCS proteins to control JAK-STAT signalling in disease. Trends Pharmacol Sci 2019;40:298–308.

27. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22:503–529.

28. Dukowski P, Oberkofler CE, Béchir M, Müllhaupt B, Geier A, Raptis DA, Clavien PA. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transplant 2011; 17:674–684.

29. Zhang Y, Xue W, Zhang W. Histone methyltransferase G9a protects against acute liver injury through GSTP1. Cell Death Differ 2020;27:1243–1258.

30. Zhou T, Sun Y, Li M, Ding Y, Yin R, Li Z, Xie Q, Bao S, Cai W. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway. Cell Death Dis 2018; 9:590.

31. Bernsmeier C, Triantafyllou E, Brenig R, Lebosse FJ, Singanayagam A, Patel VC, Pop OT, Khamri W, Nathwani R, Tidswell R, Weston CJ, Adams DH, Thursz MR, Wendon JA, Antoniades CG. CD14(+CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut 2018;67:1155–1167.

32. Huang A, Zhang B, Yan W, Wang B, Wei H, Zhang F, Wu L, Fan K, Guo Y. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. J Immunol 2014;193:5461–5469.

33. Cripps JG, Wang J, Maria A, Blumenthal I, Gorham JD. Type 1 T cell helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 2010;52:1350–1359.

34. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006;176:284–290.

35. Rodríguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007;109:1568–1573.

36. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8(+T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175:4583–4592.

37. Schübel D, MacAlpine DM, Scalzo D, Wirbelauer C, Krooiberger C, van Leeuwen F, Gottschling DE, O’Neill LP, Turner BM, Delrow J, Bell SP, Grou难得 M. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 2004;18:1263–1271.

38. Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herboldsheimer E, Zeitlinger J, Lewitter F, Gifford DK, Young RA. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 2005;122:517–527.

39. Vakoc CR, Sachdeva MM, Wang H, Blobel GA. Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol 2006;26:9185–9195.

40. Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, Ren Y, Jin Q, Dent SYR, Li W, Li H, Shi X, AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 2014;159:558–571.

41. Chen S, Yang Z, Wilkinson AW, Deshpande AJ, Sidoli S, Krajewski K, Strahl BD, Garcia BA, Armstrong SA, Patel DJ, Ozan C, The PZP domain of AF10 senses unmodified H3K27 to regulate DOT1L-mediated methylation of H3K79. Mol Cell 2015;60:319–329.

42. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Berdah S, Klentz T, Gualandi P, Kuchler K, DiMartino J, Hedrick E, Löwenberg B, Tallman MS. The DOT1L inhibitor pino-
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int 2019; 13:353–390.

Received September 6, 2020. Accepted January 14, 2021.

Correspondence
Address requests for Correspondence: Wei Cai, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, 200025, Shanghai, China. e-mail: carieyc@hotmail.com; fax: +86-21-54923270. Yanyun Zhang, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yuyang Road, Shanghai, 200031, China. e-mail: yyzhang@sibs.ac.cn; fax: +86-21-54923270. Yuting Gu, Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 160 Pujian Road, Shanghai, 200127, China. e-mail: guyutingxm@126.com; fax: +86-21-54923270.

CRediT Authorship Contributions
Wanlin Yang (Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Supervision: Lead; Writing – original draft: Lead)
Hongshuang Yu (Formal analysis: Lead; Investigation: Lead; Methodology: Lead; Writing – original draft: Lead)
Jiefang Huang (Methodology: Supporting)
Xiang Miao (Methodology: Supporting)
Qiwei Wang (Methodology: Supporting)
Yanan Wang (Funding acquisition: Supporting; Methodology: Supporting)
Yiji Cheng (Funding acquisition: Supporting; Methodology: Supporting)
Shan He (Funding acquisition: Supporting; Methodology: Supporting)
Mujen Meng (Funding acquisition: Supporting; Methodology: Supporting; Project administration: Supporting)
Bei Wang (Investigation: Supporting)
Fengtiao Qian (Methodology: Supporting)
Xiaohui Ren (Methodology: Supporting)
Min Jin (Formal analysis: Supporting; Methodology: Supporting)
Yuting Gu (Funding acquisition: Supporting; Supervision: Writing – review & editing: Equal)
Yanyun Zhang (Funding acquisition: Lead; Supervision: Equal; Writing – review & editing: Equal)
Wei Cai (Funding acquisition: Supervision: Lead; Writing – review & editing: Lead)

Conflicts of Interest
The authors disclose no conflicts.

Funding
This work was supported by the National Natural Science Foundation of China (81900565, 81800518, 82000567, 81670540, 81700656, 81873447, 81700172, 81700171, 81700170, and 81470867) and the Program of Science and Technology Commission of Shanghai Municipality (19ZR1430900 and 20ZR1433500).